People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses
出版年份 2022 全文链接
标题
People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses
作者
关键词
-
出版物
JOURNAL OF INFECTIOUS DISEASES
Volume -, Issue -, Pages -
出版商
Oxford University Press (OUP)
发表日期
2022-06-07
DOI
10.1093/infdis/jiac229
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
- (2022) Wilfredo F. Garcia-Beltran et al. CELL
- Prospective evaluation of COVID-19 vaccine responses across a broad spectrum of immunocompromising conditions: the COVICS study
- (2022) Ghady Haidar et al. CLINICAL INFECTIOUS DISEASES
- Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
- (2022) Delphine Planas et al. NATURE
- Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
- (2022) Sandile Cele et al. NATURE
- Vaccines Elicit Highly Conserved Cellular Immunity to SARS-CoV-2 Omicron
- (2022) Jinyan Liu et al. NATURE
- SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
- (2022) Rolando Pajon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durability of ChAdOx1 nCov-19 vaccination in people living with HIV
- (2022) Ane Ogbe et al. JCI Insight
- Reduced Immune Response to Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Cohort of Immunocompromised Patients in Chile
- (2022) M Elvira Balcells et al. CLINICAL INFECTIOUS DISEASES
- Characterization of the significant decline in humoral immune response six months post‐SARS‐CoV‐2 mRNA vaccination: A systematic review
- (2022) Kin Israel Notarte et al. JOURNAL OF MEDICAL VIROLOGY
- T cell responses to SARS-CoV-2 spike cross-recognize Omicron
- (2022) Roanne Keeton et al. NATURE
- Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose
- (2022) Yaniv Lustig et al. NATURE IMMUNOLOGY
- Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants
- (2022) Milja Belik et al. Nature Communications
- Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients
- (2022) Matthijs Oyaert et al. Frontiers in Immunology
- Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy
- (2022) Zabrina L. Brumme et al. npj Vaccines
- COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State
- (2021) James M. Tesoriero et al. JAMA Network Open
- Reduced humoral response to mRNA SARS‐CoV‐2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus
- (2021) Ayelet Grupper et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV
- (2021) Jake A. Ruddy et al. AIDS
- Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2
- (2021) Parakkal Deepak et al. ANNALS OF INTERNAL MEDICINE
- The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV)
- (2021) Bezawit A Woldemeskel et al. CLINICAL INFECTIOUS DISEASES
- Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1
- (2021) Itzchak Levy et al. CLINICAL MICROBIOLOGY AND INFECTION
- Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
- (2021) Sokratis A. Apostolidis et al. NATURE MEDICINE
- Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
- (2021) Angela Choi et al. NATURE MEDICINE
- SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- (2021) Ann R. Falsey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
- (2021) Yinon M. Bar-On et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
- (2021) John Frater et al. Lancet HIV
- Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
- (2021) Shabir A Madhi et al. Lancet HIV
- Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
- (2021) Amir Massarweh et al. JAMA Oncology
- Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study
- (2021) Matthias B Moor et al. Lancet Rheumatology
- Humoral response to SARS-CoV-2 vaccines in people living with HIV
- (2021) Sebastian Noe et al. INFECTION
- Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
- (2021) Shuo Feng et al. NATURE MEDICINE
- Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
- (2021) Shirley Collie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Waning Immunity after the BNT162b2 Vaccine in Israel
- (2021) Yair Goldberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plasma Neutralization of the SARS-CoV-2 Omicron Variant
- (2021) Fabian Schmidt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
- (2021) Einav G. Levin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
- (2021) Barak Mizrahi et al. Nature Communications
- A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction
- (2020) Chee Wah Tan et al. NATURE BIOTECHNOLOGY
- Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): a prospective observational study
- (2020) Anna Maria Geretti et al. CLINICAL INFECTIOUS DISEASES
- Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa
- (2020) Andrew Boulle et al. CLINICAL INFECTIOUS DISEASES
- SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
- (2020) Gregory A Poland et al. LANCET
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform
- (2020) Krishnan Bhaskaran et al. Lancet HIV
- Vaccination in the adult patient infected with HIV: a review of vaccine efficacy and immunogenicity
- (2019) Firas El Chaer et al. AMERICAN JOURNAL OF MEDICINE
- Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Long-term Immune Responses to Vaccination in HIV-Infected Patients: A Systematic Review and Meta-Analysis
- (2014) S. Kerneis et al. CLINICAL INFECTIOUS DISEASES
- Immunization for HIV-positive individuals
- (2009) Anna Maria Geretti et al. CURRENT OPINION IN INFECTIOUS DISEASES
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started